Start › Rak przełyku › Teksas › Houston
Badania kliniczne dla Rak przełyku w mieście Houston, TX
36 badań dla Rak przełyku szuka uczestników w ośrodkach w mieście Houston i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekrutacjaFaza 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekrutacjaFaza 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekrutacjaFaza 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RekrutacjaFaza 2
- MD Anderson Cancer Center (Data Collection Only), Houston
Pan-tumor MRD Study
RekrutacjaBadanie obserwacyjne
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekrutacjaFaza 1
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RekrutacjaFaza 3
- Research Site, Houston
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RekrutacjaFaza 1/2
- University of Texas MD Anderson Cancer Center ( Site 8920), Houston
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RekrutacjaFaza 1/2
- University of Texas MD Anderson Cancer Center ( Site 6920), Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Oncology Consultants, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RekrutacjaFaza 2
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekrutacjaFaza 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
RekrutacjaBadanie obserwacyjne
- M D Anderson Cancer Center, Houston
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
RekrutacjaBadanie obserwacyjneZapraszamy zdrowych ochotników
- MD Anderson Cancer Center, Houston
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
RekrutacjaFaza 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
RekrutacjaZapraszamy zdrowych ochotników
- M D Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RekrutacjaFaza 2
- M D Anderson Cancer Center, Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
RekrutacjaBadanie obserwacyjne
- Baylor College of Medicine, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RekrutacjaBadanie obserwacyjne
- Md Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
RekrutacjaFaza 1
- Baylor St. Luke's Medical Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- Oncology Consultants, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekrutacjaFaza 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Houston
Distribution of Lymph Node Metastases in Esophageal Carcinoma
RekrutacjaBadanie obserwacyjne
- MD Anderson Cancer Center, Houston
Badania dla Rak przełyku w innych miastach
- Boston, MA23 badań
- New York City, NY22 badań
- Nashville, TN19 badań
- St. Louis, MO17 badań
- Pittsburgh, PA15 badań
- Los Angeles, CA15 badań
- Grand Rapids, MI14 badań
- Baldwin Park, CA14 badań
- Philadelphia, PA13 badań
- San Antonio, TX12 badań
- Dallas, TX11 badań
- Chicago, IL11 badań
Inne badania w mieście Houston
- Niedrobnokomórkowy rak płuca145 badań
- Rak piersi126 badań
- Nowotwory (wszystkie typy)121 badań
- Nowotwór przerzutowy104 badań
- Rak jelita grubego i odbytnicy102 badań
- Rak jajnika89 badań
- Ostra białaczka szpikowa85 badań
- Rak płuc78 badań
- Rak prostaty76 badań
- Rak endometrium68 badań
- Rak trzustki61 badań
- Czerniak59 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.